Coherus BioSciences, Inc. announced the completion of the divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd. on April 11, 2025. This transaction, valued at up to $558.4 million, included an upfront cash payment of $483.4 million, with potential for an additional $75 million in milestone payments.
The successful divestiture results in a post-close cash balance of $250 million, which is projected to extend the company's cash runway over two years into 2027. This financial strengthening is crucial for funding the development of Coherus's innovative oncology pipeline through key data catalysts.
With this completion, Coherus is now exclusively focused on its novel oncology programs, including the revenue-generating PD-1 inhibitor LOQTORZI, the first-in-class IL-27 antagonist casdozokitug, and the highly selective CCR8 antibody CHS-114. Accord BioPharma, Inc., Intas's U.S. specialty division, has assumed full responsibility for the UDENYCA franchise in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.